Abstract:Recent efforts for increasing the success in drug discovery focus on an early, massive, and routine mechanistic and/or kinetic characterization of drug-target engagement as part of a design-make-test-analyze strategy. From an experimental perspective, many mechanistic assays can be translated into a scalable format on automation platforms and thereby enable routine characterization of hundreds or thousands of compounds. However, now the limiting factor to achieve such in-depth characterization at high-throughput becomes the quality-driven data analysis, the sheer scale of which outweighs the time available to the scientific staff of most labs. Therefore, automated analytical workflows are needed to enable such experimental scale-up. We have implemented such a fully automated workflow in Genedata Screener for time-dependent ligand-target binding analysis to characterize non-equilibrium inhibitors. The workflow automates Quality Control (QC) / data modelling and decision-making process in a staged analysis: (1) quality control of raw input data-fluorescence signal-based progress curves - featuring automated rejection of unsuitable measurements; (2) automated model selection - one-step versus two-step binding model - using statistical methods and biological validity rules; (3) result visualization in specific plots and annotated result tables, enabling the scientist to review large result sets efficiently and, at the same time, to rapidly identify and focus on interesting or unusual results; (4) an interactive user interface for immediate adjustment of automated decisions, where necessary. Applying this workflow to first-pass, high-throughput kinetic studies on kinase projects has allowed us to surmount previously rate-limiting manual analysis steps and boost productivity; and is now routinely embedded in a biopharma discovery research process.

Hit me with your best shot: Integrated hit discovery for the next generation of drug targets

Compound Libraries: Recent Advances and Their Applications in Drug Discovery.

Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery

Data-driven approaches used for compound library design, hit triage and bioactivity modeling in high-throughput screening

Covalent hits and where to find them

Recent advances and method development for drug target identification

Targeted Molecular Diversity in Drug Discovery: Integration of Structure-Based Design and Combinatorial Chemistry

The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit Generation

Computational approaches streamlining drug discovery

Target-based drug discovery: Applications of fluorescence techniques in high throughput and fragment-based screening

Structure-Based Virtual Screening of Chemical Libraries for Drug Discovery

State-of-the-art technology in modern computer-aided drug design

Systematic computational strategies for identifying protein targets and lead discovery

Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals

Machine Learning Assisted Hit Prioritization for High Throughput Screening in Drug Discovery

What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets

High-throughput mechanistic screening of non-equilibrium inhibitors by a fully automated data analysis pipeline in early drug-discovery

Increasing the Odds of Drug Hit Identification by Screening Against Receptor Homologs?

Proteomic methods for drug target discovery

Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification